Indusatumab vedotin

Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin. Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis[1].

1514889-12-3

MLN0264; TAK-264

12352203

Antibody-Drug Conjugates (ADCs) ; Apoptosis; Guanylate Cyclase

Antibody-drug Conjugate/ADC Related; Apoptosis; GPCR/G Protein

Cancer-programmed cell death

Cancer

96.37

10 mM in DMSO

[Indusatumabvedotin]

[1]Schreiber AR, et al. Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. Clin Cancer Drugs. 2018;5 (1) :42-49. |[2]Teng S W, et al. Using pharmacokinetic/efficacy modeling to identify the optimal schedule for MLN0264, an anti-guanylyl cyclase C (GCC) antibody-drug conjugate, in a range of xenograft models[J]. Cancer Research, 2014, 74 (19_Supplement) : 4649-4649.

Dry Ice

-80°C, protect from light

http://file.medchemexpress.com/batch_PDF/HY-P99662/Indusatumab-vedotin-SDS-MedChemExpress.pdf

ADC Related

Phase 2